Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 12  |  Issue : 1  |  Page : 238-243

Survival and prognostic factors in limited stage small cell lung cancer: A retrospective study from northeast Turkey


Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey

Correspondence Address:
Özlem Aynaci
Karadeniz Technical University, Faculty of Medicine, Department of Radiation Oncology, Trabzon - 61080
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.151446

Rights and Permissions

Aim of the Study: The purposes of this retrospective study were to identify survival rates for limited stage small cell lung cancer (LD-SCLC) and analyze treatment outcomes and influencing factors on survival. Materials and Methods: We conducted data from patients diagnosed with LD.SCLC between January 1998 and December 2012 at our institution. Dermographic information, treatment modalities, pretreatment clinical asessment, were recorded. Most of the patients. (88.4%) were treated with curative intent. The survival probabilties were asessed by Kaplan.Meier analysis. Cox regression was used to assess prognostic factors on overall survival and disease.free survival. Results: A total of 129 patients were examined as a LD-SCLC. The median age was 60 (range; 31–86). Median follow-up time was 9.4 (SE ± 20.5) months and the median overall survival was 13.9 months [95% cumulative incidence (CI): 10.1–17.6]. On multivariate analysis, concurrent chemotherapy [HZ: 2.7 (95% CI: (1.0–7.2)] (P = 0.037) and doses of radiation therapy (<50, ≥50) [HZ: 1.4 (95% CI: (1.0–2.2)] (P = 0.046) were statistically significant on overall survival. With regard to multivariate anlaysis age (<60, ≥60) [HZ: 2.2 (95% CI: (0.6–3.7)] (P = 0.011), doses of radiation therapy (<50, ≥50) [HZ: 2.7 (95% CI: (1.0–7.2)] (P = 0.046), precense of surgery [HZ: 15.3 (95% CI: (1.5–152)] (P = 0.020), prophilactic cranial radiation therapy (PCI) [HZ: 2.3 (95% CI: (1.1–4.5)] (P = 0.014), and presence of concurrent chemoradiotherapy [HZ: 3.0 (95% CI: (1.3–6.8)] (P = 0.008) were important variable affecting disease-free survival. Conclusion: For LD-SCLC patients concurrent chemoradiation therapy and 50. Gy and over doses radiation therapy provided improvement on overall and disease.free survival.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3665    
    Printed70    
    Emailed0    
    PDF Downloaded194    
    Comments [Add]    

Recommend this journal